Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Phenobarbital After Neonatal Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Birth at \> 34 weeks' gestation~* Neonatal seizures (clinical, electrographic or both), with onset in the first 120 hours after birth and resolution within 7 days of onset~* Parental informed consent~Exclusion Criteria:~* Birth at \< 34 weeks' gestation~* If the attending neonatologist attributes the seizures solely to a transient abnormality, easily correctable and unlikely to recur (eg, transient electrolyte abnormalities). If the attending neonatologist cannot be contacted, the site PI will be asked to review the available information and judge whether the infant is eligible.~* If the infant has been diagnosed with or there is a strong suspicion of an inborn error of metabolism, significant brain malformation, microcephaly (\< 3 %ile), or a chromosomal abnormality which, in the absence of seizures, is known to be independently associated with an increased likelihood of cognitive impairment~* If the infant has been diagnosed with an intrauterine viral infection~* If the infant is not expected to survive to discharge

- Gender: ALL
- Minimum Age: 2 Days
- Maximum Age: 2 Weeks
- Healthy Volunteers: f

Study Arms:
- Phenobarbital (Type: ACTIVE_COMPARATOR): Phenobarbital, 4-5 mg/kg/day, for 4 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo in a volume equivalent to active drug for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).